✨Excited and honored to can finally share our work about the rare and important subgroup of POLE/D1 proofreading deficient (pd) mCRC treated with ICIs across 🇪🇺🇺🇸🇮🇱

Filippo Pietrantonio Paolo Manca Benoit JC Rousseau

ESMO - Eur. Oncology Annals of Oncology

authors.elsevier.com/sd/article/S09…

For details🧵⬇️

Thrilled to see our work in print today Annals of Oncology!
Awesome international collaboration led by Filippo Pietrantonio and a great pleasure to work with the very talented Margherita Ambrosini to assemble the largest cohort of POLE/POLD1 proofreading deficient #colorectal cancer. Thread⬇️

Super happy for an incredibly talented fellow, Margherita Ambrosini and thanks to the key expert Benoit JC Rousseau and all co-authors who contributed, and Annals of Oncology for recognizing the importance of academic orginal research on precision medicine ESMO - Eur. Oncology

The ESMO - Eur. Oncology guidlines gives a stronger support (I,A) for adjuvant pembrolizumab in appropriate intermediate & high risk renal cancer due to +ve OS signal Toni Choueiri, MD Belzutifan is also recommended in VHL germ line altered localised RCC Annals of Oncology ow.ly/nZA050RP77l

Updated clear cell renal cancer guidlines ESMO - Eur. Oncology.Ipi/nivo now has additional weak support in IMDC good risk (I,C). Belzutifan gets strong support in 3rd line (I,B) but less strong 2nd line (VEGF TKI preferred).1st line PD1/VEGF unchanged Annals of Oncology ow.ly/nZA050RP77l

New ESMO - Eur. Oncology guidlines in advance papillary renal cancer. While there is randomised data supporting Cabo (PFS not OS) sunitinib is still weakly supported. The single arm Len/pem & Cabo/nivo data look more active and is also recommend. 2nd line data needed ow.ly/nZA050RP77l

In Annals of Oncology, Professor Georgina Long AO and coll. report on the 5⃣-year outcomes from a ph2 trial of neoadjuvant BRAFi dabrafenib & MEKi trametinib for stage IIIB–C BRAF V600E/K-mutant melanoma:

❓Does pCR correlate with RFS?
❓How do results compare to IO?

annalsofoncology.org/article/S0923-…

Biomarker data from adjuvant ipi/nivo vs placebo study in #BreastCancer shows Kidney injury marker-1 (KIM-1), which is overexpressed and prognostic, may be important (along with PD-L1) in response to ipi/nivo. Patient selection for adjuvant IO is important. #AnnOnc #ESMOBreast24

The Lancet ☢️RADICALS-RT follow-up results confirm there is no clear evidence of a benefit of giving radiotherapy soon after surgery for everyone, compared to only giving radiotherapy if the cancer returns.

The results are published in Annals of Oncology👇 9/10
sciencedirect.com/science/articl…

🆕New results from our RADICALS #ProstateCancer trial can help guide decisions about treatment.

RADICALS explored the best way to use radiotherapy (RT) and/or hormone therapy (HD) after surgery. Follow this thread to learn about the findings👇🧵
youtu.be/o8UbJtP8l8E

Results from the FIH study of first-in-class CDK4-selective inhibitor PF-07220060 with ET in HR+ HER2-MBC after prior CDK4/6i,
✅G3 neutropenia rate=18.2% (no G4)
✅ORR=32%, CBR=64%
✅PFS=8.1mo
👉Promising data as CDK4/6i move to the adjuvant setting
#AnnOnc #ESMOBreast24

Presented at #ESMOBreast24 reassuring evidence for the #oncofertility counselling of young #BRCA carriers wishing to conceive after #BreastCancer : fertility techniques can be safely used without apparent negative effects on maternal prognosis or fetal outcomes.
#AnnOnc

Presented by Rebecca Dent at #ESMOBreast24 w/ simultaneous publication in Annals of Oncology 1st results of Impassion132 showing no benefit of adding #atezoliyumab to 1st line CT in pts w/ advanced #TNBC relapsing <12months.
#AnnOnc #BreastCancer tinyurl.com/5n99udja

🆕The latest Annals of Oncology article of the month podcast 🎙️ is out!

EiC Tom Powles discusses with
Giorgio Bogani the role of immunotherapy in the 1st-line setting for advanced endometrial cancer.

Soundcloud:
soundcloud.com/esmo-podcasts/…

Spotify: open.spotify.com/episode/3HlxTY…